MentionFox
Home › IPO pipeline › Exxel Pharma, INC.
IPO filings · Form S-1, F-1, 424B4, RW

Exxel Pharma, INC. IPO

Exxel Pharma, INC.'s initial public offering: every registration filing, amendment, final prospectus and withdrawal, with the facts quoted from the filings and each one linked.

StatusAmended
TickerEXXL
ExchangeNYSE American
First filed2025-09-19
Filings3

Exxel Pharma, INC. filed a Form S-1 registration statement for an initial public offering on 2025-09-19. It has amended it 2 times. As of its latest filing, on 2026-02-02, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

What the filings say

Listing

We intend to apply for listing of our common stock on the NYSE American under the symbol “EXXL”.From the S-1/A filed 2026-02-02

Use of proceeds

We intend to use the net proceeds from this offering, along with our existing cash and cash equivalents, for clinical trials and product development, research and development, clinical manufacturing as well as for working capital and other general corporate purposes.From the S-1/A filed 2026-02-02

Revenue

For the six months ended June 30, 2025, revenue decreased by approximately $175,000, or 100%, compared to the prior year period, due to the termination of licensing agreement at the end of the prior fiscal year.From the S-1/A filed 2025-10-14

Net loss or income

For the years ended December 31, 2024 and 2023, we reported net losses of $409,171 and $430,098, respectively, and as of December 31, 2024 and December 31, 2023, we had accumulated deficits of $4,010,601 and $3,601,430, respectively.From the S-1/A filed 2026-02-02

Timeline

FiledWhat it isFiling
2025-09-19Registration statement filedS-1
2025-10-14Registration statement amendedS-1/A
2026-02-02Registration statement amendedS-1/A

Tools for this story

Each opens in a new tab, filled in for Exxel Pharma, INC.. With no account yet, you sign up free and land on the result.

Where this comes from

A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.

Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/ipo/exxel-pharma
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3
Exxel Pharma, INC. IPO (EXXL, NYSE American): registration amended. MentionFox, 2026-09-27. https://mentionfox.com/ipo/exxel-pharma